Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
2018 · Journal of Translational Medicine · 120 citations
https://doi.org/10.1186/s12967-018-1452-4
J
Jeremy Tchack
Yale University(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
25
Papers
305
Citations
7
h-index
6
i10-index
Jeremy Tchack is an academic researcher from Yale University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Melanoma and MAPK Pathways. The author has an h-index of 7, co-authored 22 publications.
Papers by this author
worksImmunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
2018 · Journal of Translational Medicine · 28 citations
https://doi.org/10.1186/s12967-017-1352-z
MOESM1 of Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
2016 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.c.3609854_d4
MOESM2 of Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
2016 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.c.3609854_d2
Supplementary Material for: Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care
2017 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.5097322
MOESM6 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
2018 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.6072584
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat